Sumgen Biotech

Sumgen Biotech is a clinical-stage biopharmaceutical company based in Shanghai, China, focused on the discovery and development of innovative antibody-based therapeutics for cancer treatment. The company utilizes its proprietary technology platforms to engineer next-generation biologics, including monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs). Sumgen's pipeline features several high-potential candidates targeting PD-1, PD-L1/TGF-beta, CD47, and Claudin 18.2, with multiple programs currently in clinical trials. By integrating internal R&D with state-of-the-art GMP manufacturing, the company aims to deliver effective and accessible precision medicines to patients globally.